pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
Théa Pharma Ireland
Verona Pharma Ireland Limited
Théa Pharma Ireland clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Castlebar, IE
- Founded
- 2018
- Employees
- 19
- Programs
- 11
- Drugs
- 42
- Patents
- 0
Théa Pharma Ireland projects
4 ClinicalTrials.gov programs sponsored by Théa Pharma Ireland.
Théa Pharma Ireland has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CRCFC-TEICO.SA.2022
Verona Pharma Ireland Limited
cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection
1 trial -
INCIPIT
Verona Pharma Ireland Limited
multifocal spasticity of the upper and lower limb due to cerebral palsy
1 trial -
PASSION
Verona Pharma Ireland Limited
Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy
1 trial -
TAMOXENE 20 mg compresse rivestite con film
Verona Pharma Ireland Limited
cystic fibrosis
1 trial
Frequently asked questions
How many clinical projects does Théa Pharma Ireland have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.